About Genentech

For more than 40 years, Genentech has pursued groundbreaking science to discover and develop innovative medicines for people facing serious and life-threatening diseases. Their transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis. They are investing more in research and development than any other healthcare company to fuel the future of scientific discovery.

Investing in America

  • Including one of the largest biologics facilities in the world, Roche and Genentech have 5 U.S. manufacturing and distribution facilities.
  • Over the past 5 years, they have invested $4 billion in infrastructure.
  • Roche and Genentech have almost 25,000 full-time U.S. employees.
  • 21 years as one of Fortune’s “Best Companies to Work For”.
  • 11 years as Dow Jones’ most sustainable healthcare company.
  • 18 years On Science Magazine’s “Top Employer” list.

Genentech Commitment to Patients

Invest in Breakthrough Research:

  • Last year, Roche invested approximately $11 billion in R&D - more than any other healthcare company in the world.
  • Genentech and Roche have received 28 FDA Breakthrough Therapy Designations for medicines that have the potential to provide substantial improvement over currently available treatments.
Address Unmet Medical Needs:
  • Genentech and Roche make ~40 medicines to help people with serious and life- threatening diseases.
  • Their focus for the future remains on serious and difficult-to-treat conditions such as Alzheimer’s, Parkinson’s, cancer, hemophilia, autoimmune diseases and multidrug-resistant bacterial infections.

Approach to Pricing & Access

Launch Prices:

  • Over the last several years, we have priced our newly launched medicines below other approved medicines used to treat the same disease.
  • We priced OCREVUS® (ocrelizumab) at 25% below the medicine it surpassed in clinical trials, and HEMLIBRA® (emicizumab-kxwh) at less than half the cost of standard treatment for this type of hemophilia (a rare disease).
Support Access to Genentech and Roche Medicines:
  • Genentech and Roche assistance programs have helped more than 2 million Americans access our therapies.
  • They provide free medicine to 60,000 eligible patients each year.
  • Last year, they provided approximately $5.8 billion in government discounts.


Joaquín Castañeda
Director, State & Local Government Affairs

Learn More

Follow Genentech on LinkedIn, Twitter, Facebook, Instagram, YouTube and visit